Type 1 diabetes (T1D) prevention trials can be shortened if intermediate endpoints indicative of a very high risk of progression are reached before diagnosis. Since Index60, a composite C-peptide and glucose measure, has been shown to have potential use as such an endpoint, we evaluated additional combinations of C-peptide and glucose as endpoints. Diabetes Prevention Trial-type 1 participants (n=702) with baseline values below threshold (set arbitrarily at 95th percentile for each endpoint) were followed at 0.5-1.0 year intervals with 2-hour OGTTs for the first (incident) OGTT that thresholds were exceeded. Participants were then followed for T1D. All endpoints were reached, on average, over 1 year prior to the diagnosis of T1D. Risks for subsequent T1D after the incident OGTT were substantial, but variable (3-year risk=0.66-0.81). There was also appreciable variation in numbers reaching endpoints (n=55-117) and positive predictive values for T1D (PPV=62-77%). Ages were lowest for Glucose/C-peptide measures at incident OGTTs. Index60 performed best regarding key endpoint criteria: number reaching endpoint, 3-year risk, and PPV.

In conclusion, individuals highly likely to ultimately develop T1D can be identified over 1 year before diagnosis by combined C-peptide and glucose endpoints. It appears that such endpoints should be considered for T1D prevention trials.


L.M. Jacobsen: None. M.A. Clements: Advisory Panel; Self; Glooko, Inc. Consultant; Self; Eli Lilly and Company. Speaker's Bureau; Self; Medtronic. M.J. Redondo: None. B.M. Nathan: None. D. Schatz: None. J.M. Sosenko: None.


National Institutes of Health; JDRF

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.